XNK Therapeutics’ vision is to develop a broad platform technology for NK cell-based therapies based on a proprietary method for expanding and activating the patient’s own NK cells.

XNK is currently developing the platform technology and CellProtect for patients diagnosed with multiple myeloma and also intends to apply the technology for other cancer-related indications pertaining to both hematological and solid tumors. The company’s goal is for the platform technology to become an important and natural component in tomorrow’s cancer treatment.